Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset

Download Results

Project #	Project Title	Research Focus Area	Research Program	Administering IC	Institution(s) Sort ascending	Investigator(s)	Location(s)	Year Awarded
1R21DA047662-01 Show Summary	Human laboratory model to screen drugs with opioid analgesic-sparing effects: cannabidiol/morphine combinations	Novel Therapeutic Options for Opioid Use Disorder and Overdose	Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose	NIDA	WAYNE STATE UNIVERSITY	Lundahl, Leslie H	Detroit, MI	2019
NOFO Title: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) NOFO Number: PA-18-344 Summary: Chronic pain is a significant public health problem associated with tremendous personal and economic burden. First-line treatment consists of opioid medications, but despite only moderate efficacy and unpleasant side effects, rates of opioid prescriptions have quadrupled over the past 15 years, and this has contributed to high rates of misuse, overdose, and mortality. Clearly, alternative, or non-opioid strategies for treating pain are needed. In this context, “opioid-sparing” medications refer to compounds that can be combined with and enhance the analgesic effects of lower-dose opioids without increasing the rewarding properties of either drug. There is preclinical evidence suggesting that cannabidiol (CBD) may have the potential to function as “opioid-sparing” medications, but its ability to alter opioid-mediated analgesia in humans has yet to be determined. This proposal will fill this gap by conducting a double-blind, placebo-controlled, within-subject randomized crossover study of the effects of CBD and morphine co-administration on pain sensitivity and subjective reinforcement on 28 healthy males and females. This is the first known study to investigate the ability of CBD to alter morphine’s analgesic effects in humans. If successful, the model will have a lasting impact on our ability to develop and test medications that reduce our reliance on chronic use of opioid medications for pain relief.
1U01HL150551-01 Show Summary	Dual-orexin antagonism as a mechanism for improving sleep and drug abstinence in opioid use disorder	New Strategies to Prevent and Treat Opioid Addiction	Sleep Dysfunction as a Core Feature of Opioid Use Disorder and Recovery	NHLBI	Wayne State University	GREENWALD, MARK K (contact); ROEHRS, TIMOTHY A	Detroit, MI	2019
NOFO Title: HEAL Initiative: Sleep and Circadian-Dependent Mechanisms Contributing to Opiate Use Disorder (OUD) and Response to Medication Assisted Treatment (MAT) (U01 Clinical Trial Optional) NOFO Number: RFA-HL-19-029 Summary: FDA-approved medications for treating opioid use disorder are effective, but there is a significant unmet need for alternatives, especially relapse prevention. NIDA and the FDA have encouraged investigators to expand the range of therapeutic outcomes, beyond measurement of abstinence. Insomnia is a clinically significant, but understudied, correlate/predictor of relapse to substance use. Yet most medications for treating insomnia have limited efficacy and can produce side effects. The orexin (OX) system plays a key role in sleep and substance use, offering a promising avenue for study. This project will address whether OX-1/2 antagonism is a mechanism that can directly improve outpatient opioid abstinence, or whether OX antagonism corrects sleep deficiencies and indirectly improves opioid abstinence. Specific aims are to determine whether nightly treatment with the OX-1/2 antagonist suvorexant, relative to placebo, 1) increases outpatient opioid abstinence and 2) improves sleep efficiency on the residential detoxification unit. The study will also determine 3) whether improved sleep efficiency predicts greater opioid abstinence (regardless of group assignment).
1R44DA058431-01 Show Summary	Development of an AI-Empowered Device that Utilizes Multimodal Data-Visualization to Aid in the Diagnosis, and Treatment, of OUD	Cross-Cutting Research	Small Business Programs	NIDA	WAVI COMPANY	ARESE LUCINI, FRANCESCA	Englewood, CO	2023
NOFO Title: Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) NOFO Number: RFA-DA-23-021 Summary: There are a lack of clinical tools to effectively identify and monitor opioid use disorder (OUD). This project will develop and test a clinically usable device that uses a range of data inputs and an artificial intelligence (AI) algorithm to help health care providers diagnose and treat OUD. The research aims to help providers choose treatment plans and monitor the timing of release from rehabilitation clinics.
3R01DK103901-04S1 Show Summary	TARGETING THE TRANSIENT RECEPTOR POTENTIAL CHANNELS TO IMPROVE BOWEL DYSFUNCTION	Preclinical and Translational Research in Pain Management		NIDDK	WASHINGTON UNIVERSITY	HU, HONGZHEN	SAINT LOUIS, MO	2018
NOFO Title: Research Project Grant (Parent R01) NOFO Number: PA-13-302 Summary: Postoperative ileus (POI) following gastrointestinal (GI) surgery leads to significant patient morbidity and prolonged hospitalizations. Recent studies have demonstrated that intestinal manipulation and surgical trauma activate inflammatory macrophages (M?) and release inflammatory mediators such as nitric oxide (NO) to inhibit intestinal smooth muscle cells in POI. Intestinal M? are a highly heterogeneous and dynamic population in the innate immune system. Preliminary studies show that transient receptor potential vanilloid 4 (TRPV4) channel, a molecular sensor of tissue damage and inflammation, is exclusively expressed by the F4/80+/CD206+ intestinal anti-inflammatory M2 M?. Activation of TRPV4 produces an intestinal contractile response and improves GI transit in a mouse model of POI. The current proposal aims to elucidate the cellular and molecular mechanisms underlying the activation of TRPV4 in the intestinal M2 M?.
1R21NS132565-01 Show Summary	Discovery of the Novel Targets for Post-Traumatic Headache	Preclinical and Translational Research in Pain Management	Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain	NINDS	WASHINGTON UNIVERSITY	CAO, YUQING	Saint Louis, MO	2023
NOFO Title: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) NOFO Number: RFA-TR-22-011 Summary: Chronic post-traumatic headache (PTH) is highly debilitating, poorly understood, and difficult to treat. This project aims to identify proteins located in the membrane of certain neurons that are critical for the development, maintenance, and/or resolution of PTH. These proteins may be targets for novel treatment approaches that are nonaddictive and have minimal side effects.